Can You Have Melanoma for Years and Not Know It?

Melanoma can absolutely go unnoticed for years, and it does so more often than most people realize. Some subtypes spend a decade or longer in a slow, flat growth phase that produces only subtle changes in a mole or patch of skin. Others hide in places you would never think to check, or lack the dark coloring most people associate with skin cancer. The biology of the disease itself adds another layer: melanoma cells can scatter to distant tissues and then sit quietly, sometimes for more than ten years, before waking up. Understanding how and why this happens is the difference between catching the disease early and finding it after it has already spread.

How Long the Slow Phase Can Last

Most melanomas begin with what dermatologists call a radial growth phase, where the cancer cells spread outward across the surface of the skin rather than burrowing deeper. During this phase, the tumor is generally incapable of spreading to lymph nodes or distant organs. A study of 234 patients with superficial spreading melanomas found that those whose tumors were still confined to this radial phase were, on average, about 4.3 years younger than patients whose tumors had progressed to a deeper, more dangerous vertical growth phase. That age gap is essentially a rough proxy for how long the indolent phase lasted before the tumor shifted gears.¹

Not every melanoma follows the same timeline, though. Lentigo maligna, a subtype that tends to appear on chronically sun-damaged skin in older adults, is one of the slowest. Estimates suggest it can take anywhere from 10 to 50 years for lentigo maligna to progress into invasive lentigo maligna melanoma, and the overall risk of that transformation may be under five percent.² That means a person could have a slowly expanding brown patch on their face for decades without it ever becoming life-threatening, and also without them suspecting cancer.

When researchers compared growth rates across melanoma subtypes, the numbers were strikingly different. Superficial spreading melanomas thickened at a median rate of about 0.12 mm per month. Lentigo maligna melanomas were similar at 0.13 mm per month. Nodular melanomas, by contrast, grew at 0.49 mm per month, roughly four times faster.³ A tumor adding just 0.12 mm of thickness each month could easily fly under the radar for years, especially if it is in a spot you do not regularly inspect.

When It Hides in Plain Sight

Most public awareness campaigns focus on the classic warning signs: a dark, irregularly shaped, asymmetric mole that changes over time. That description fits the majority of melanomas, but a meaningful subset simply does not look the part. Amelanotic melanoma produces little or no pigment, so it can appear pink, red, or even skin-colored. Because it does not match what people expect melanoma to look like, diagnosis is frequently delayed, and most patients with amelanotic melanoma already have advanced disease by the time it is identified.⁴

The well-known ABCDE checklist (Asymmetry, Border irregularity, Color variation, Diameter, Evolution) has been used for nearly 30 years as a screening tool for both doctors and the public.⁵ It works well for the most common presentations, but it was never designed to catch every melanoma. Nodular melanomas are often symmetrical and uniformly colored. Amelanotic melanomas may check none of the boxes. Relying on the checklist alone gives a false sense of security, and it can lead someone to dismiss a lesion that does not fit the expected pattern.

Locations That Get Overlooked

Where melanoma grows on the body matters enormously for how quickly it gets caught. Acral lentiginous melanoma, the type that develops on palms, soles, and under fingernails or toenails, is especially prone to diagnostic delays. It tends to show up in areas people do not routinely examine, and it does not fit the “changing mole” pattern that most awareness messaging targets.⁶

The subungual form, which grows under a nail, is particularly treacherous. It often starts as a brownish or blackish streak on the nail and gets misdiagnosed as a fungal infection, a bruise, or a wart. Roughly 85% of subungual melanoma cases are initially misdiagnosed.⁷ One study found that misdiagnosis of subungual melanomas led to a median delay of 18 months, while palmoplantar melanomas were delayed by a median of 12 months. In 85% of the misdiagnosed cases, the initial wrong call was made by a non-dermatologist.⁸

Mucosal melanomas are even harder to detect. These arise on the moist tissue lining the mouth, nasal passages, gastrointestinal tract, or genitals. Because these are hidden sites that produce no externally visible lesion, and because early symptoms are vague or absent, mucosal melanomas are overwhelmingly diagnosed late.⁹ A spot inside your nasal cavity is not something you can check in a mirror, and a melanoma on the lining of the rectum might not produce any noticeable symptoms until it is fairly advanced.

What a Delay Actually Costs

Melanoma survival hinges on how thick the tumor is when it is removed. Thickness is a function of time: the longer a melanoma grows before it is caught, the deeper it extends and the more likely it is to have spread.¹⁰ The practical stakes of a diagnostic delay are severe. In a study of melanomas on the foot, tumors that were initially misdiagnosed averaged 3.7 mm in thickness compared with 1.9 mm for correctly diagnosed tumors. The five-year overall survival rate was about 64% in the misdiagnosed group versus roughly 88% in those caught correctly the first time.¹¹

A machine-learning analysis of more than 800 superficial spreading melanomas attempted to identify the diameter at which tumors transition from the indolent radial growth phase to the more dangerous vertical phase. For non-nevus-associated tumors, the threshold was about 13.2 mm.¹² That figure is not a magic cutoff, but it gives a rough sense of the point at which a slowly expanding spot starts becoming more dangerous. Years of slow radial expansion can eventually cross that line.

Dormancy and Late Recurrence

One of the more unsettling aspects of melanoma biology is that the cancer can spread microscopically long before the primary tumor is detected, and those scattered cells can then lie dormant for years. Disseminated melanoma cells may sit quietly in distant tissues, held in check by signals from their microenvironment and by the immune system, without forming a detectable tumor.¹³ This dormancy explains the phenomenon of late recurrence, where a patient who had a melanoma removed and appeared cancer-free for a decade or more suddenly develops metastatic disease.

Ultra-late recurrences, appearing 10 to 15 years after initial treatment, are well documented in melanoma. Research in animal models has shown that melanoma cells that successfully infiltrate organs like the liver or lung can enter a prolonged state of quiet rather than immediately proliferating. Immune surveillance may also play a role in keeping small clusters of cancer cells from expanding.¹⁴ Between 40 and 50 percent of uveal (eye) melanomas remain undetected for longer than a decade after initial dissemination, compared with fewer than five percent of cutaneous melanomas.¹³ The mechanics of what triggers reactivation are still not fully understood, which makes long-term follow-up after melanoma treatment genuinely important.

Melanoma of Unknown Primary

In a small but significant fraction of melanoma cases, patients show up with metastatic disease in their lymph nodes or other organs, but doctors cannot find the original skin lesion that started it all. These are classified as melanomas of unknown primary. The leading explanation is that the original tumor underwent spontaneous regression, meaning the immune system destroyed the primary lesion on the skin while disseminated cells survived elsewhere.¹⁵

Genetic profiling of these tumors supports that theory. Melanomas of unknown primary carry a mutation profile consistent with sun-exposed skin, suggesting that a substantial proportion of them started as cutaneous melanomas that either regressed completely or were so inconspicuous they were never noticed.¹⁶ In other words, you can have melanoma, have your immune system clear the visible evidence of it from your skin, and still end up with metastatic cancer years later. That is a particularly disorienting scenario for patients, but it underscores how the disease can remain hidden even from the body’s own defenses.

Genetic Variation in Growth Speed

Not all melanomas of the same subtype grow at the same rate. The specific mutations driving the cancer influence how quickly it progresses. In a study of 196 melanomas, tumors carrying the BRAF V600E mutation, the most common oncogenic mutation in melanoma, actually tended to grow more slowly than tumors with the rarer BRAF V600K mutation or NRAS mutations. The rates were roughly 0.12 mm per month for BRAF V600E versus 0.61 mm per month for BRAF V600K.¹⁷ Paradoxically, the slower-growing BRAF V600E melanomas were associated with worse melanoma-specific survival when adjusted for other factors, possibly because their slower growth allows them more time to seed metastases before they are noticed.

Another study found that BRAF V600E-mutant melanomas actually grew faster in terms of surface area than those without the mutation (about 3.4 mm² per year versus 1.6 mm² per year), while melanomas that retained expression of the tumor suppressor protein p16 grew more slowly than those that had lost it.¹⁸ The apparent discrepancy between these two studies reflects different measurement methods (thickness per month versus surface area per year) and different cohorts, but the takeaway is consistent: molecular variation creates a wide range of growth behaviors. Some melanomas sit around for years barely changing; others accelerate quickly. You cannot tell which type you have by looking at it.

Why People Wait to See a Doctor

Even when a melanoma is visible and changing, patients frequently delay seeking medical attention. Research into patient psychology around moles and skin cancer shows that the path from noticing a change to actually seeing a doctor is rarely straightforward. People tend to evaluate their moles by comparing them with what they consider a “normal” mole on their own body or on someone they know. They infer that something is wrong mainly when they notice a change in size or when the lesion starts causing physical symptoms like pain or bleeding.¹⁹ A melanoma that grows slowly, stays flat, and does not hurt provides very little of the sensory feedback that triggers alarm.

There is also a strong role played by personal experience: people who have seen a relative or friend go through skin cancer are more attuned to changes and more likely to consult a doctor early. Those without that reference point may normalize a slowly evolving lesion for years, telling themselves it is just a mole getting bigger with age. This psychological dimension is an underappreciated reason melanomas go undetected, separate from the biology of the tumor itself.

Disparities in Who Gets Caught Late

Melanoma is far less common in people with darker skin, but when it does occur, it is disproportionately diagnosed at a later stage. Part of this gap is biological: melanoma in darker-skinned individuals more often arises on acral sites like the palms, soles, and nails, which are locations that, as discussed earlier, are prone to long diagnostic delays regardless of the patient’s skin tone. But the gap is also systemic. Lower public awareness that melanoma can affect people of all skin colors, combined with disparities in healthcare access and lower provider awareness of atypical presentations, contribute to delayed diagnosis.²⁰ If you have been told your whole life that skin cancer is a “fair-skinned person’s disease,” you are much less likely to think twice about a dark streak under your toenail.

The Role of Dysplastic Nevi

Another source of confusion is the dysplastic nevus, or atypical mole. These moles sit in a gray zone between a normal mole and melanoma in terms of their appearance and cellular structure. They are often larger, more irregular, and more variably colored than typical moles. While the chance that any single dysplastic nevus will transform into melanoma is very low, having multiple dysplastic nevi is a strong marker of overall melanoma risk.²¹ For people with many atypical moles, telling the difference between “just another funny-looking mole” and an actual melanoma can be genuinely difficult, even for dermatologists. This can create a monitoring burden that paradoxically leads to both over-biopsy and under-detection, depending on the clinical setting.

Technology That Aims to Close the Gap

Total body photography, where standardized photos of your entire skin surface are taken at regular intervals so changes can be spotted by comparison, has shown promise for catching melanomas earlier. A systematic review covering more than 12,000 individuals found that people undergoing total body photography tended to have thinner melanomas at diagnosis and a higher proportion of in situ (non-invasive) melanomas compared with those who were not photographed.²² The approach is most practical for high-risk individuals, such as those with a personal or family history of melanoma or a large number of atypical moles.

Artificial intelligence is also entering the picture. In one study using sequential dermoscopic images, an AI model correctly identified early melanomas at a higher rate than clinicians (about 64% versus 54%) and flagged them earlier in the monitoring timeline, correctly diagnosing about 61% of melanomas on the first follow-up image compared with roughly 33% for the clinicians.²³ These tools are not yet standard of care, but they point to a future where the kinds of subtle, slow changes that allow melanomas to hide in plain sight for years might be caught by algorithms trained to spot what human eyes miss.

What You Can Do With All of This

The practical upshot is that self-exams should go well beyond checking your most obvious moles. Inspect the soles of your feet, the spaces between your toes, your nails (including toenails), and any area of skin you do not normally see. Ask a partner or use a mirror for your back and scalp. Do not limit your mental model of melanoma to a dark, ugly mole: pay attention to pink or skin-colored bumps that persist and grow, and to dark streaks under nails that were not there before. If you have many atypical moles or a family history of melanoma, talk to a dermatologist about whether total body photography or more frequent skin checks make sense. And if you have had a melanoma removed in the past, continue follow-up for many years afterward, because dormant cells can reactivate long after the original tumor is gone.